- Home
- IMCR vs VSAT Comparison
IMCR vs VSAT Comparison
Compare IMCR & VSAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- VSAT
- Stock Information
- Founded
- IMCR 2008
- VSAT 1986
- Country
- IMCR United Kingdom
- VSAT United States
- Employees
- IMCR N/A
- VSAT N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- VSAT Radio And Television Broadcasting And Communications Equipment
- Sector
- IMCR Health Care
- VSAT Technology
- Exchange
- IMCR Nasdaq
- VSAT Nasdaq
- Market Cap
- IMCR 1.6B
- VSAT 1.9B
- IPO Year
- IMCR 2021
- VSAT 1996
- Fundamental
- Price
- IMCR $35.00
- VSAT $14.60
- Analyst Decision
- IMCR Buy
- VSAT Buy
- Analyst Count
- IMCR 10
- VSAT 7
- Target Price
- IMCR $58.13
- VSAT $20.00
- AVG Volume (30 Days)
- IMCR 383.2K
- VSAT 3.5M
- Earning Date
- IMCR 08-07-2025
- VSAT 08-06-2025
- Dividend Yield
- IMCR N/A
- VSAT N/A
- EPS Growth
- IMCR N/A
- VSAT N/A
- EPS
- IMCR N/A
- VSAT N/A
- Revenue
- IMCR $333,581,000.00
- VSAT $4,519,571,000.00
- Revenue This Year
- IMCR $26.82
- VSAT $4.46
- Revenue Next Year
- IMCR $8.15
- VSAT $3.58
- P/E Ratio
- IMCR N/A
- VSAT N/A
- Revenue Growth
- IMCR 25.75
- VSAT 5.50
- 52 Week Low
- IMCR $23.15
- VSAT $6.69
- 52 Week High
- IMCR $41.54
- VSAT $26.70
- Technical
- Relative Strength Index (RSI)
- IMCR 59.78
- VSAT 60.99
- Support Level
- IMCR $32.20
- VSAT $14.31
- Resistance Level
- IMCR $35.75
- VSAT $16.20
- Average True Range (ATR)
- IMCR 1.31
- VSAT 0.78
- MACD
- IMCR 0.28
- VSAT -0.05
- Stochastic Oscillator
- IMCR 84.94
- VSAT 53.27
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About VSAT ViaSat Inc.
Viasat Inc provides bandwidth technologies and services in three segments: communication services and defense and advanced technologies. The communication services segment provides a wide range of broadband and narrowband communications solutions across government and commercial mobility markets, as well as for residential and enterprise fixed broadband customers: and the defense and advanced technologies segment develops and offers a diverse array of resilient, vertically integrated solutions to government and commercial customers, leveraging core technical competencies in encryption, cyber security, tactical gateways, modems and waveforms. A large majority of the firm's revenue is generated from communication services segment.